Scientists discover new way to tackle inflammatory diseases

by Shemina Davis
Scientists discover new way to tackle inflammatory diseases
Zebrafish inflammatory neutrophils (in red) leave sites of inflammation when treated with Tanshinone

Researchers at the University of Sheffield have found a potential new way to treat common and largely incurable inflammatory conditions like chronic obstructive pulmonary disease (COPD).

Normally when a person is injured or gets an infection, the body sends specialist white blood cells (neutrophils) to clean up the area, resulting in it becoming red and inflamed. The inflammation usually ebbs away over time but in certain diseases the inflammation remains, doing more damage to surrounding tissue.

Now scientists from the University of Sheffield may have found a solution using an ingredient found in traditional Chinese medicine which has inflammation reducing capabilities, giving it the potential to treat a range of diseases.

By screening drugs in zebrafish, researchers found a compound, Tanshinone IIA, which reduced inflammation, removing neutrophils by causing them to die at the wound and by moving them away from the wound - a completely new way to treat . The discovery has, for the first time, given scientists the opportunity to develop anti-inflammatory drugs which would not increase the risk of infection like current treatments.

Professor Stephen Renshaw, from the University's Department of Infection and Immunity, said: "Chronic inflammatory diseases are a major cause of illness and death worldwide and many of these, such as chronic (COPD) are characterised by the persistence of inflammatory neutrophils. We believe targeting the neutrophil would be a new way to bring about healing in these conditions.

"Sending immune cells away from damaged tissue might be a good way to allow the damage to heal while still allowing those to protect us against infection."

Professor Renshaw said it was not known at the moment precisely how Tanshinone IIA helps to migrate away from the wound but said research would continue.

He added: "Tanshinone IIA might be the first in a new class of drugs that allows us to tackle some devastating conditions, benefiting thousands of sufferers."

The research work was funded by the Medical Research Council (MRC) and the full paper will be published in the Science Translational Medicine journal.

Related Stories

Nanoparticles target anti-inflammatory drugs where needed

date Feb 23, 2014

Researchers at the University of Illinois at Chicago have developed a system for precisely delivering anti-inflammatory drugs to immune cells gone out of control, while sparing their well-behaved counterparts. ...

New blood cells fight brain inflammation

date Feb 16, 2014

Hyperactivity of our immune system can cause a state of chronic inflammation. If chronic, the inflammation will affect our body and result in disease. In the devastating disease multiple sclerosis, hyperactivity of immune ...

Recommended for you

'Google Maps' for the body: A biomedical revolution

date 2 hours ago

A world-first UNSW collaboration that uses previously top-secret technology to zoom through the human body down to the level of a single cell could be a game-changer for medicine, an international research ...

New compounds could offer therapy for multitude of diseases

date 3 hours ago

An international team of more than 18 research groups has demonstrated that the compounds they developed can safely prevent harmful protein aggregation in preliminary tests using animals. The findings raise hope that a new ...

Novel nanoparticle therapy promotes wound healing

date Mar 26, 2015

An experimental therapy developed by researchers at Albert Einstein College of Medicine of Yeshiva University cut in half the time it takes to heal wounds compared to no treatment at all. Details of the therapy, ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.